Hepcidin agonists, including synthetic peptides and small molecules that enhance hepcidin activity, represent promising approaches for treating iron overload disorders such as hereditary hemochromatosis and in patients on regular blood transfusions (3). The gene discussed is HAMP; the disease is hereditary hemochromatosis.